Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Handelsbanken Fonder AB

Handelsbanken Fonder AB increased its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 8.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 18,867 shares of the company’s stock after buying an additional 1,500 shares during the quarter. Handelsbanken Fonder AB’s holdings in Neurocrine Biosciences were worth $2,486,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Headinvest LLC acquired a new position in Neurocrine Biosciences in the 3rd quarter worth about $28,000. Lindbrook Capital LLC raised its holdings in Neurocrine Biosciences by 85.0% in the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock worth $28,000 after purchasing an additional 96 shares during the period. BluePath Capital Management LLC acquired a new position in Neurocrine Biosciences in the 3rd quarter worth about $35,000. Sunbelt Securities Inc. raised its holdings in Neurocrine Biosciences by 34.3% in the 3rd quarter. Sunbelt Securities Inc. now owns 325 shares of the company’s stock worth $37,000 after purchasing an additional 83 shares during the period. Finally, Fifth Third Bancorp raised its holdings in Neurocrine Biosciences by 51.3% in the 3rd quarter. Fifth Third Bancorp now owns 622 shares of the company’s stock worth $70,000 after purchasing an additional 211 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on NBIX shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a report on Tuesday. Mizuho increased their target price on Neurocrine Biosciences from $116.00 to $140.00 and gave the company a “neutral” rating in a report on Thursday, February 8th. Oppenheimer reissued an “outperform” rating and set a $200.00 target price on shares of Neurocrine Biosciences in a report on Wednesday. Wells Fargo & Company raised Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $140.00 to $170.00 in a report on Wednesday. Finally, Citigroup reduced their target price on Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating for the company in a report on Thursday, February 8th. Six research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Neurocrine Biosciences has an average rating of “Moderate Buy” and a consensus price target of $142.38.

Neurocrine Biosciences Stock Performance

Shares of Neurocrine Biosciences stock opened at $135.99 on Friday. The firm has a market capitalization of $13.53 billion, a price-to-earnings ratio of 56.19 and a beta of 0.25. Neurocrine Biosciences, Inc. has a fifty-two week low of $89.04 and a fifty-two week high of $148.37. The stock has a 50 day moving average of $136.63 and a 200 day moving average of $127.85.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, topping the consensus estimate of $1.13 by $0.31. The company had revenue of $515.20 million during the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The firm’s revenue for the quarter was up 25.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.88 earnings per share. Analysts forecast that Neurocrine Biosciences, Inc. will post 4.83 EPS for the current year.

Insider Buying and Selling

In other news, CEO Kevin Charles Gorman sold 2,707 shares of the firm’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $140.69, for a total transaction of $380,847.83. Following the completion of the transaction, the chief executive officer now directly owns 502,188 shares in the company, valued at $70,652,829.72. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, CFO Matt Abernethy sold 1,283 shares of the firm’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $140.72, for a total transaction of $180,543.76. Following the completion of the transaction, the chief financial officer now directly owns 28,284 shares in the company, valued at $3,980,124.48. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Kevin Charles Gorman sold 2,707 shares of the firm’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $140.69, for a total value of $380,847.83. Following the transaction, the chief executive officer now owns 502,188 shares of the company’s stock, valued at $70,652,829.72. The disclosure for this sale can be found here. Over the last three months, insiders sold 186,994 shares of company stock worth $25,806,409. Company insiders own 4.40% of the company’s stock.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.